NEWS TRENDS ANALYSIS :: THE OBSERVATORY
In men, the greatest incidence rate increase was seen in pancreatic cancer, which increased by 1.1% per year, and the steepest incidence rate decrease was seen in lung cancer, which fell by 2.6% per year. In women, melanoma had the steepest increase in incidence, rising by 1.8% per year, and thyroid cancer had the sharpest decrease, falling by 2.9% per year. Overall cancer incidence rates dur- ing 2014 to 2018 were highest among non-Hispanic American Indian and Alaska Native (AI/AN) people, fol- lowed closely by non-Hispanic White people and non-Hispanic Black people. Overall cancer incidence rates were lowest among non-Hispanic Asian/Pacific Islander (API) and His- panic people.
Incidence rates for all sites combined
decreased among non-Hispanic Black, non-Hispanic API, and Hispanic men, but increased among non-Hispanic White, non-Hispanic API, non-His- panic AI/AN, and Hispanic women from 2014 to 2018. Incidence rates were stable among non-Hispanic White and non-Hispanic AI/AN men and non- Hispanic Black women. Among children younger than 15,
overall cancer death rates decreased from 2015 to 2019, and incidence rates remained stable from 2014 to 2018. Overall cancer incidence rates were stable for non-Hispanic Black children over this period but increased for non-Hispanic White, non-Hispanic API, non-Hispanic AI/ AN, and Hispanic children.
Among adolescents and young adults ages 15 to 39, overall cancer incidence rates increased by 0.9% per year from 2014 to 2018. The overall cancer death rate decreased by 3.0% per year from 2001 to 2005, but the decline slowed to 0.9% per year from 2005 to 2019. The incidence of breast cancer, the
most common cancer among adolescents and young adults, increased by an aver- age of 1.0% per year from 2010 to 2018. The researchers noted that racial and
ethnic disparities exist for many indi- vidual cancer sites. For example, from 2014 to 2018, incidence rates for bladder cancer declined in non-Hispanic White, non-Hispanic Black, non-Hispanic API, and Hispanic men but increased among non-Hispanic AI/AN men. Incidence rates for uterine cancer increased among women of every racial and ethnic group from 2014 to 2018 except for non-Hispan- ic White women, who had stable rates. From 2015 to 2019, prostate cancer
death rates were stable among non- Hispanic White and non-Hispanic Black men but decreased among non- Hispanic API, non-Hispanic AI/AN, and Hispanic men. Colorectal cancer death rates were stable among non- Hispanic AI/AN men but decreased in men of all other racial and ethnic groups. Among women, death rates for lung, breast, and colorectal cancer decreased in nearly every racial and ethnic group. The exceptions were non- Hispanic API women, among whom breast cancer death rates remained stable, and non-Hispanic AI/AN women, among whom breast cancer
death rates increased and colorectal cancer death rates remained stable. This year’s report includes a special focus on trends in pancreatic cancer incidence, death, and survival rates. Although pancreatic cancer accounts for only 3% of new cancer diagnoses, it accounts for 8% of cancer deaths and is the fourth leading cause of cancer deaths in the United States for both men and women.
Study finds personalized kidney screening for people with type 1 diabetes could reduce costs, detect disease earlier
Taking a personalized approach to kid- ney disease screening for people with type 1 diabetes (T1D) may reduce the time that chronic kidney disease (CKD) goes undetected, according to a new analysis performed by the Epidemi- ology of Diabetes Interventions and Complications study group. The finding was published in Diabe- tes Care and provides the basis for an evidence-based kidney screening model for people with T1D. According to the model’s findings:
• People with AER of 21-30 mg per 24 hours and a HbA1c of at least 9% are at high risk for developing CKD and could be screened for urine albumin every six months.
• Those with AER ≤ 10 mg per 24 hours and a HbA1c ≤ 8% are at lower risk for developing CKD and could be screened every two years.
• All others with T1D ≥ 5 years could continue to be screened annually.
Which COVID vaccine you get can impact myocarditis risk
Incidence of myocarditis, pericar- ditis or myopericarditis is two- to threefold higher after a second dose of the Moderna Spikevax COVID- 19 vaccine when compared to the Pfizer BioNTech COVID-19 vaccine; however, overall cases of heart inflammation with either vaccine are very rare, according to a study in the Journal of the American College of Cardiology.
The study showed males younger than 40 years old who received the Moderna vaccine were shown to have the highest rates of myocarditis, which according to the authors, may have implications for choosing specific vaccines for certain populations.
While there have been many studies on either vaccine, few studies have been conducted to
directly compare the safety of the two mRNA vaccines. Researchers in this study sought to compare the risk of myocarditis, pericarditis and myopericarditis between the Pfizer and Moderna COVID-19 vaccines. People in the study were 18 years old or older and had received two primary doses of either Pfizer or Moderna vaccine in British Colum- bia, Canada, with the second dose between Jan. 1, 2021 and Sept. 9, 2021. Individuals whose first or second shot were administered outside of British Columbia or had a history of myocarditis or pericarditis within one year prior to second dose were excluded. In all, more than 2.2 million second Pfizer doses were given and more than 870,000 Moderna doses. Within 21 days of the
second dose, there were a total of 59 myocarditis cases (21 Pfizer and 31 Moderna) and 41 pericarditis cases (21 Pfizer and 20 Moderna). Researchers also looked at rates per million doses and the rate was 35.6 cases per million for Moderna and 12.6 per million for Pfizer—an almost threefold increase after Moderna shots vs. Pfizer. Com- paratively, rates of myocarditis in the general population in 2018, were 2.01 per million in people under age 40 and 2.2 per million in people over age 40. Rates of myocarditis and peri- carditis were higher with the Moderna vaccine in both males and females between ages 18 and 39, with the highest per million rates in males ages 18-29 after a second dose of Moderna.
MLO-ONLINE.COM DECEMBER 2022 7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
